EGF and neoplasm: Similar to our previous experiments, EGF further enhanced tumor cell MAPK pathway activity and PD‐L1 expression, which was counteracted by erlotinib and selumetinib, without influencing MHC‐I (Figure 6A,B and supplementary material, Figure S6A).